

Rheumatology Treatments

Reference Number: RDF1212-23

Date of Response: 26/01/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Please see below Trust response. Please note:-

<5 In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

Drug	Trust service area totals – Eastern & Northern (joint)
Abatacept [Orencia]	25
Adalimumab [Humira]	20
Adalimumab Biosimilars	216
Apremilast [Otezla]	7
Baricitinib [Olumiant]	75
Certolizumab [Cimzia]	60
Etanercept [Enbrel]	*<5
Etanercept Biosimilars	109
Filgotinib [Jyseleca]	42
Golimumab [Simponi]	87
Guselkumab [Tremfya]	*<5
Infliximab [Remicade]	*<5
Infliximab Biosimilars	22
Ixekizumab [Taltz]	13
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	0
Rituximab Biosimilars	35
Sarilumab [Kevzara]	6
Secukinumab [Cosentyx]	27
Tocilizumab [Ro Actemra]	38
Tofacitinib [Xeljanz]	21
Upadacitinib [Rinvoq]	86
Ustekinumab [Stelara]	*<5

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs.

Drug	Trust service area totals – Eastern & Northern (joint)
Adalimumab [Humira]	5
Adalimumab Biosimilars	23
Certolizumab [Cimzia]	6
Etanercept [Enbrel]	*<5
Etanercept Biosimilars	0
Golimumab [Simponi]	0
Infliximab [Remicade]	0
Infliximab Biosimilars	0
Ixekizumab [Taltz]	0
Secukinumab [Cosentyx]	*<5
Tofacitinib [Xeljanz]	0
Upadacitinib [Rinvoq]	6